HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis.

Abstract
Antituberculosis therapy-associated cutaneous leukocytoclastic vasculitis (CLV) has been rarely reported. We describe a case of CLV induced by rifampicin and pyrazinamide. A 14-year-old male diagnosed with disseminated tuberculosis developed purpuric lesions after 1.5 months of treatment. Histopathology was consistent with leukocytoclastic vasculitis. Skin lesion improved after cessation of the two drugs and treatment with corticosteroids.
AuthorsVidyut Bhatia, Anupam Sibal, Shilpy Rajgarhia
JournalJournal of tropical pediatrics (J Trop Pediatr) Vol. 59 Issue 6 Pg. 507-8 (Dec 2013) ISSN: 1465-3664 [Electronic] England
PMID23780994 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antitubercular Agents
  • Pyrazinamide
  • Prednisolone
  • Rifampin
Topics
  • Adolescent
  • Antitubercular Agents (adverse effects)
  • Humans
  • Male
  • Prednisolone (administration & dosage)
  • Pyrazinamide (adverse effects)
  • Rifampin (adverse effects)
  • Treatment Outcome
  • Tuberculosis (drug therapy)
  • Vasculitis, Leukocytoclastic, Cutaneous (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: